嶋澤 るみ子

Shimazawa Rumiko

  • 教授
  • 学位:博士(薬学)

基本情報

所属

  • Undergraduate School of Medicine / Faculty of Medicine
  • Graduate School of Medicine / Course of Advanced Medical Science
  • Graduate School of Medicine / Course of Medical Science
  • Graduate School of Medicine / Course of Nursing

詳細情報

研究分野

  • Life sciences Healthcare management, medical sociology

論文

Potential adverse events in Japanese women who received tozinameran (BNT162b2, Pfizer-BioNTech).

Approvals of type 2 diabetes drugs tested in cardiovascular outcome trials: A tripartite comparison

Regulatory perspectives on next-generation sequencing and complementary diagnostics in Japan.

Imbalance in glycemic control between the treatment and placebo groups in cardiovascular outcome trials in type 2 diabetes

Challenges to hemoglobin A1c as a therapeutic target for type 2 diabetes mellitus

Natural language processing-based assessment of consistency in summaries of product characteristics of generic antimicrobials.

Pharmacogenomic biomarkers: Interpretation of information included in United States and Japanese drug labels

Pharmacogenomic biomarkers on drug labels: interpretation of United States and Japanese labels based on Pharmacogenetics Knowledgebase

Approval status and evidence for WHO essential medicines for children in the United States, United Kingdom, and Japan: A cross-sectional study

Overcoming regulatory challenges in the development of companion diagnostics for monitoring and safety

Drug-diagnostic co-development: challenges and issues

DEVELOPMENT OF DRUG-APPROVAL REGULATIONS FOR MEDICAL COUNTERMEASURES AGAINST CBRN AGENTS IN JAPAN

International differences in companion diagnostic approvals: how are we able to manage the differences?

Conflicts of interest in psychiatry: Strategies to cultivate literacy in daily practice

Guidance for peptide vaccines for the treatment of cancer

Approval gap of pharmacogenomic biomarkers and in vitro companion diagnostics between the United States and Japan

Differences in pharmacogenomic biomarker information in package inserts from the United States, the United Kingdom and Japan

Are there any differences in the regulations of personalized medicine among the USA, EU and Japan?

Safety information in drug labeling: a comparison of the USA, the UK, and Japan

The vaccine gap between Japan and the UK

書籍等出版物

  • Companion and Complementary Diagnostics: From Biomarker Discovery to Clinical Implementation
  • Companion Diagnostics (CDx) in Precision Medicine
  • Retinoids: Progress in Research and Clinical Applications

講演・口頭発表等

  • 有害物質暴露等の対応を目的とした医薬品確保対策の国際比較
  • 添付文書における安全性記載の日米欧三極比較
  • 含窒素複素環カルベンを基盤とするC‐S二座型配位子を用いたパラジウム触媒による有機ホウ素試薬の付加反応と応用
  • C‐S二座配位子‐パラジウム触媒を用いた有機三フッ化ホウ素塩のアルデヒドへの付加反応
  • 親水性基と疎水性基の組合せによる新規Cdc25A阻害剤
  • 複素環カルベンを基盤とするC‐S二座配位子―パラジウム触媒による有機ホウ酸試薬を用いたアルデヒドへの付加反応
  • 含窒素ヘテロ環カルベンを基盤とした新規C‐S二座型配位子の開発と鈴木‐宮浦カップリングへの応用
  • 環状イミド型COX阻害剤の創製
  • 生物薬品承認審査上の規格・安定性分野について 審査報告書の事例を踏まえ
  • 医薬品承認審査上の規格・安定性分野について 審査報告書の事例を踏まえ
  • 各種バイオファクターのPDI阻害活性
  • 医薬品承認審査上の規格・安定性関連分野について 具体的事例を踏まえ
  • 新医薬品承認審査上の規格・安定性関連分野における問題点について
  • 41 MOLECULAR FUNCTION OF ANTITUMOR-ANTIBIOTICS DYNEMICIN A : SYNTHESIS OF AZA-ATHRAQUINONES AS DNA INTERCALATER

所属学会

  • PARENTERAL DRUG ASSOCIATION JAPAN CHAPTER
  • THE PHARMACEUTICAL SOCIETY OF JAPAN

共同研究・競争的資金等の研究課題

Study on drug utilization, research and development of intractable disease treatment using the database

Drug information and prescription for older adults

Study on effective drug safety information based on investigation of boxed warning

How to develop a good patient information leaflet of a medicine

Assessment of regulatory efforts to facilitate the approval of off-label drugs

Regulatory science research on drug develpment, review, and post-marketing regulation

Development of novel class of Cdc25A inhibitor by combination of hydrophilic and hydrophobic group

Total synthesis of Salinosporamide A, a potent proteasome inhibitor

ResearchMapへ移動します

Contact Us

Inquiries about coverage

Public Affairs Division Public Affairs and Communications Department

Tel. 0463-63-4670(direct dialing)